Synergy CHC Corp.
SNYRQ Healthcare Medical Distribution
Synergy CHC Corp.’s revenue for fiscal 2025 (year ended December 2025) was $30.4 million, down 12.8% from fiscal 2024. In the quarter to March 2026, revenue fell 32.8%, EPS fell 330.0%, free cash flow fell 148.5% and total debt rose 7.08%, each against the same quarter a year earlier.
Follow SNYRQ
Synergy CHC Corp. (SNYRQ) P/E ratio
Synergy CHC Corp. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 20.6× (October 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 15.9× | (22.93%) |
| FY2023 | 20.6× | 0.00% |
| FY2022 | 20.6× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 8.4× | 12.18% |
| Jun 2025 | 7.5× | (4.61%) |
| 6 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACH Accendra Health, Inc. compare | n/m |
| FOCL FocalTherics compare | n/m |
| AHG Akso Health Group Sponsored ADR compare | n/m |
| COSM Cosmos Health Inc. compare | n/m |
| SNYRQ Synergy CHC Corp. | n/m |
| YI 111, Inc. Sponsored ADR compare | n/m |
| HSIC Henry Schein, Inc. compare | 25.0× |
| CAH Cardinal Health, Inc. compare | 35.0× |
| HKPD Cellyan Biotechnology Co., Ltd compare | — |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)